Denise Neves Gameiro, Author at Labiotech.eu - Page 8 of 24

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

pili tolouse white biotechnology twb bioreactor

News and Trends 20 Jul 2016

SynBio Startup moves to Toulouse to scale up its Bacterial Ink Production

Pili is leaving its bio-hacking nest in Paris for the industrial facilities of TWB, Toulouse’s preindustrial demonstrator for industrial Biotech. It will be able to develop pilot-scale production of its first dye – blue… Pili is one of the examples of Biotech innovation coming out of biohacking spaces. The start-up started at La Paillasse (Paris) and went on […]

July 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

redhill biopharma nih ebola animal rule fda

News and Trends 20 Jul 2016

Israeli Biopharma joins NIH to develop Ebola Treatment

RedHill Biopharma has announced a research collaboration with the NIH. The focus will be RedHill’s new experimental treatment for Ebola, after encouraging results in preliminary studies. The Ebola outbreak of 2014 in West Africa highlighted the need for a therapy against this infectious disease, which has mortality rate ranging from 25% to 90%. The crisis spurred a […]

July 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

immunoqure autoantibodies therapeutic apeced

News and Trends 19 Jul 2016

German Biotech studies Autoimmune Diseases to develop new Therapeutics

Patients suffering from a rare autoimmune disorder could actually be the key for a new promising type of antibodies. These are the findings of researchers from ImmunoQure and different European universities, now published in Cell. More than 40 years ago, the development of monoclonal antibodies really pushed the class of biologics forward. Research on antibodies […]

July 19, 2016 - 3 minutesmins - By Denise Neves Gameiro

poxel euronext paris diabetes type 2 glimins japan

News and Trends 19 Jul 2016

Poxel raises €26.5M to support Phase III trial in Diabetes

Poxel has closed a capital increase on the Euronext Paris, raising €26.5M. The money is intended to fund its plans to tackle the $4Bn Japanese market for Type 2 diabetes. Biotech is tackling diabetes with many different approaches, from new oral drugs to MedTech and cell therapy. In particular, type 2 diabetes (connected to a […]

July 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

car t cd19 fda juno therapeutics cerebral edema

News and Trends 18 Jul 2016

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after 3 deaths, which could be treatment-related. How will this impact the field, given that most CAR-T Biotechs share the same target? UPDATE (article originally published on 8/7/2016): the FDA has allowed Juno Therapeutics to resume its CAR-T trial with […]

July 18, 2016 - 5 minutesmins - By Denise Neves Gameiro

genomics proteomics merger syngis expedeon biotech

News and Trends 15 Jul 2016

These Two ‘Omics’ Companies are Merging to Create a New Player in Life Sciences

Sygnis is planning to acquire Expedeon, to join its portfolio in NGS reagents with Expedeon’s presence in the proteomics market – and become a leading player in life science reagents. UPDATE (article originally published on June 6th, 2016): Sygnis successfully completes Rights Offering and Private Placement and secured the acquisition of Expedeon Holdings Ltd. on July 15th, 2016. See […]

July 15, 2016 - 4 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

abbvie ablynx rheumatoid arthritis nanobody

News and Trends 11 Jul 2016

Nanobody Phase II Results for Arthritis: Good but not good enough?

Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie to stick to the previous $840M deal is still unclear. Ghent-based Ablynx has hooked several big Pharmas with its Nanobody platform, based on the shorter monoclonal antibodies of llamas. One of these is AbbVie (France), which is […]

July 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

horama gene therapy ophtalmology retina

News and Trends 8 Jul 2016

French Startup raised €4M for Gene Therapy to fix specific Types of Blindness

Horama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M in its Series A round, which will speed up development of two candidates. Eye disorders are a popular indication for gene therapies, especially after the first gene therapy approvals – uniQure’s Glybera and GSK’s Strimvelis. Some other players in ophthalmologic […]

July 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

cormorant interleukin 8 bms immuno oncology

News and Trends 7 Jul 2016

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant – a Biotech developing immunotherapies in a deal that could go up to €460M. Based at the Karolinska Institute Science Park in Stockholm (Sweden), Cormorant was a private Biotech focusing on cancer immunotherapies. Its main program was HuMax-IL8, which is currently in Phase […]

July 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

carbios pla metabolic pathway inra insa

News and Trends 7 Jul 2016

Engineered Microorganisms now able to directly produce Bioplastics for 3D-Printing

Carbios made a breakthrough in the production of PLA, a common bioplastic. The lactic acid used as molecular ‘building blocks’ were already bio-sourced, but now the plastic can be really produced from scratch with microorganisms. Bioplastics are one of the ways GreenTech is trying to save the world. Some success stories are Bio-On’s potato plastics […]

July 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

tigenix takeda stem cell therapy crohns fistula

News and Trends 6 Jul 2016

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

TiGenix is licensing the rights for its cell therapy which is under EMA review and is meant to treat a serious complication of Crohn’s disease. This worldwide exclusivity deal (with exception to the US) could be worth up to €380M. Back in 2009, Leuven-based TiGenix was the first to launch at cell-based product (ChondroCellect) on the European market. […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

failure biotech clinical trials june

News and Trends 6 Jul 2016

June was a Tough Month for European Biotech… #Fail

Abivax, Celyad, Circassia and Genticel – these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now? Four different public Biotechs suffered setbacks in some of their advanced clinical trials. And, as always, the words ‘failed to meet primary endpoint‘ weren’t very popular with investors… […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT